Skip to content
by Legal Desire
24 September 2026

Baker McKenzie Advises Bayer on the Sale of Cancer Treatment Stivarga® to Grünenthal

Advising firms

Deal team

20 lawyers named
LawyerFirmSeniorityPracticeOffice
Daniel Dehghanian Lead Baker McKenzie Partner Corporate/M&A Düsseldorf
Jan Kresken Baker McKenzie Partner Antitrust & Competition Düsseldorf
Dr. Jan Gutsche Baker McKenzie Senior associate Corporate/M&A Düsseldorf
Dr. Martin Altschwager Baker McKenzie Partner Pharma Frankfurt
Anna Fischer Baker McKenzie Associate Pharma Frankfurt
Dr. Nicolas Kredel Baker McKenzie Partner Antitrust & Competition Düsseldorf
Dr. Florian Kotman Baker McKenzie Partner Antitrust & Competition Düsseldorf
Creighton Macy Baker McKenzie Partner Antitrust & Competition Washington, D.C.
Marisa Dieken Baker McKenzie Senior associate Antitrust & Competition Washington, D.C.
Evan Harris Baker McKenzie Senior associate Antitrust & Competition Washington, D.C.
Kirk Crawford Baker McKenzie Other Antitrust & Competition Washington, D.C.
Oksana Simonova Baker McKenzie Partner Antitrust & Competition Kyiv
Volodymyr Nazarchuk Baker McKenzie Associate Antitrust & Competition Kyiv
Seonho Kim Baker McKenzie Partner Antitrust & Competition Seoul
Patrick Wilkening Baker McKenzie Partner IP/IT Düsseldorf
Yannick Filoda Baker McKenzie Associate IP/IT Düsseldorf
Anela Winzig Baker McKenzie Associate IP/IT Frankfurt
Anahita Thoms Baker McKenzie Partner International Commercial & Trade Berlin
Frederik Alexander Dörr Baker McKenzie Associate International Commercial & Trade Berlin
Chiara Marinozzi Baker McKenzie Partner International Commercial & Trade Milan

17 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
EUR 375m (EUR 375 million)
What the figure measures
Total transaction value
Client
Bayer AGSell-side
Counterparties
Grünenthal (Buy-side)